Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction
– Financing led by Foresite Capital, Samsara BioCapital and venBio Partners with participation from additional new and existing investors –– Proceeds will support ongoing comprehensive mid to late-stage clinical development program for ESK-001 in plaque psoriasis, systemic lupus erythematosus (SLE) and uveitis –– Alumis will continue to explore ESK-001’s potential application in other immune-mediated diseases, […]
